PSHI Praxis GmbH

At PSHI Praxis GmbH researchers focus on cardiovascular disease and high blood pressure, aiming to improve blood pressure control for patients at risk.

• Blood pressure reduction strategies
• Resistant hypertension management
• Safety profiling of new antihypertensive agents
• Impact on systolic blood pressure

The work seeks to identify effective treatments that lower cardiovascular risk for individuals with uncontrolled hypertension.

The clinic investigates the intersection of type 2 diabetes and heart disease, evaluating therapies that may reduce heart‑failure events and improve survival.

• Diabetes‑related cardiovascular risk
• Combination therapy efficacy
• Hospitalization for heart failure
• Mortality reduction in diabetic patients

Researchers aim to demonstrate that adding novel agents can improve outcomes for patients with both diabetes and established cardiovascular disease.

Studies explore synergistic drug pairs such as vicadrostat with empagliflozin to address multiple risk factors in one regimen.

• Dual‑targeted treatment approaches
• Metabolic and blood pressure control
• Clinical benefit of combined agents
• Real‑world effectiveness assessment

The goal is to prove that combined therapy offers superior protection against cardiovascular death and heart failure compared with single‑agent use.

A trial evaluates Lorundrostat as an add‑on to standard antihypertensive therapy for patients with resistant hypertension.

• Add‑on therapy evaluation
• Systolic blood pressure outcomes
• Safety in difficult‑to‑treat hypertension
• Patient response monitoring

The study aims to confirm that the new agent can significantly lower systolic pressure when conventional treatments are insufficient.